0001564590-22-019861.txt : 20220512 0001564590-22-019861.hdr.sgml : 20220512 20220512161137 ACCESSION NUMBER: 0001564590-22-019861 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 22917912 BUSINESS ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92037 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92037 8-K 1 mtcr-8k_20220512.htm 8-K mtcr-8k_20220512.htm
false 0001634379 0001634379 2022-05-12 2022-05-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

 

Metacrine, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39512

47-2297384

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

4225 Executive Square, Suite 600

San Diego, California

 

92037

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 369-7800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

MTCR

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ 

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2022, Metacrine, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

The following exhibit is furnished with this Current Report.

 

Exhibit

Number

 

Description

99.1

 

Press release dated May 12, 2022.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Metacrine, Inc.

 

 

 

 

Date: May 12, 2022

 

By:

/s/ Michael York

 

 

 

Michael York

 

 

 

Chief Business Officer

 

2

 EX-99.1 2 mtcr-ex991_6.htm EX-99.1 mtcr-ex991_6.htm

Exhibit 99.1

 

METACRINE REPORTS first-QUARTER 2022 RESULTS

SAN DIEGO – May 12, 2022 - Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update.

Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated may include a merger, sale, or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of its programs.

 

“Our cash position through 2023 provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “As we assess potential strategic alternatives, we have delayed clinical development efforts related to our planned Phase 2a clinical trial of MET642 for the treatment of Ulcerative Colitis.”

First-Quarter 2022 Financial Results

 

•

Cash Balance - Cash, cash equivalents and short-term investments were $62.7 million as of March 31, 2022. Metacrine believes it has sufficient capital to fund its current operating plan through 2023.

 

 

•

R&D Expenses - Research and development expenses were $6.7 million for the three months ended March 31, 2022, as compared to $10.9 million for the prior-year period. The decrease was primarily driven by lower clinical development costs related to the advancement of our MET409 and MET642 programs.

 

 

•

G&A Expenses - General and administrative expenses were $5.5 million for the three months ended March 31, 2022, as compared to $3.7 million for the prior-year period. The increase was attributable to higher employee-related costs and expenses associated with operating as a publicly traded company.

 

 

•

Restructuring Charges - Restructuring charges were $0.9 million for the three months ended March 31, 2022, as compared to none for the prior-year period. Restructuring charges were attributable to the restructuring plan implemented in February 2022. The restructuring plan was completed in April 2022.

 

 

•

Gain from Lease Termination and Asset Sale – Gain from lease termination and asset sale was $0.5 million for the three months ended March 31, 2022, as compared to none for the prior-year period. The gain from lease termination and asset sale was related to the termination of the facility lease for our former corporate headquarters and sale of certain personal property in March 2022.

 

 

•

Net Loss - Net loss was $12.9 million for the three months ended March 31, 2022, as compared to $14.8 million for prior-year period.

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies to treat gastrointestinal diseases.  Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. To learn more, visit www.metacrine.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements about the design, progress, timing, scope and results of clinical trials; plans for initiating future clinical trials and studies; plans for optimizing Metacrine’s capital resources; anticipated drivers of value; and statements about Metacrine’s evaluation of strategic alternatives. Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely,” ”anticipate,” “estimate,” “intend,” “potential,” “prepare,” “perceived,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks related to Metacrine’s ability to identify and consummate strategic alternatives that yield additional value for stockholders; the timing, benefits and outcome of Metacrine’s strategic alternatives review process, including the determination of whether or not to pursue or consummate any strategic alternative; the structure, terms and specific risks and uncertainties associated with any potential strategic transaction; potential disruptions in Metacrine’s business and the stock price as a result of the evaluation of strategic alternatives or the public announcement thereof and any decision or transaction resulting from such evaluation; potential delays in initiating, enrolling or completing any clinical trials; competition from third parties; and Metacrine’s ability to obtain, maintain and protect its intellectual property. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Metacrine’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2022, and in Metacrine’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to

update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Investor & Media Contact

Investor Relations

Metacrine, Inc.

investors@metacrine.com


 

Metacrine, Inc.

Unaudited Condensed Consolidated Statements of Operations

(In thousands)

 

 

Three Months Ended

 

 

March 31,

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

$

6,680

 

 

$

10,857

 

General and administrative

 

5,482

 

 

 

3,696

 

Restructuring charges

 

858

 

 

 

—

 

Gain from lease termination and asset sale

 

(508

)

 

 

—

 

Total operating expenses

 

12,512

 

 

 

14,553

 

Loss from operations

 

(12,512

)

 

 

(14,553

)

Total other income (expense)

 

(368

)

 

 

(215

)

Net loss

$

(12,880

)

 

$

(14,768

)

 


 

 

Metacrine, Inc.

Unaudited Condensed Consolidated Balance Sheets

(In thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash, cash equivalents, and short-term investments

 

$

62,689

 

 

$

76,427

 

Prepaid expenses and other current assets

 

 

4,047

 

 

 

2,313

 

Total current assets

 

 

66,736

 

 

 

78,740

 

Property and equipment, net

 

 

—

 

 

 

347

 

Operating lease right-of-use asset

 

 

—

 

 

 

902

 

Total assets

 

$

66,736

 

 

$

79,989

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

264

 

 

$

368

 

Accrued and other current liabilities

 

 

5,209

 

 

 

7,392

 

Total current liabilities

 

 

5,473

 

 

 

7,760

 

Long-term debt, net of debt discount

 

 

13,425

 

 

 

13,303

 

Other long-term liabilities

 

 

1,388

 

 

 

1,571

 

Stockholders’ equity

 

 

46,450

 

 

 

57,355

 

Total liabilities and stockholders’ equity

 

$

66,736

 

 

$

79,989

 

 

 EX-101.SCH 3 mtcr-20220512.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mtcr-20220512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Central Index Key Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 mtcr-20220512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Entity Registrant Name Metacrine, Inc.
Document Period End Date May 12, 2022
Entity Central Index Key 0001634379
Entity File Number 001-39512
Entity Incorporation State Country Code DE
Entity Tax Identification Number 47-2297384
Entity Address, Address Line One 4225 Executive Square,
Entity Address, Address Line Two Suite 600
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 369-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol MTCR
Security Exchange Name NASDAQ
XML 7 mtcr-8k_20220512_htm.xml IDEA: XBRL DOCUMENT 0001634379 2022-05-12 2022-05-12 false 0001634379 8-K 2022-05-12 Metacrine, Inc. DE 001-39512 47-2297384 4225 Executive Square, Suite 600 San Diego CA 92037 858 369-7800 false false false false Common Stock, par value $0.0001 per share MTCR NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mtcr-8k_20220512.htm mtcr-20220512.xsd mtcr-20220512_lab.xml mtcr-20220512_pre.xml mtcr-ex991_6.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mtcr-8k_20220512.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mtcr-8k_20220512.htm" ] }, "labelLink": { "local": [ "mtcr-20220512_lab.xml" ] }, "presentationLink": { "local": [ "mtcr-20220512_pre.xml" ] }, "schema": { "local": [ "mtcr-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mtcr", "nsuri": "http://www.metacrine.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220512.htm", "contextRef": "C_0001634379_20220512_20220512", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220512.htm", "contextRef": "C_0001634379_20220512_20220512", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.metacrine.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-22-019861-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-019861-xbrl.zip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end